Evers, S.S.* ; Shao, Y.* ; Ramakrishnan, S.K.* ; Shin, J.H.* ; Bozadjieva-Kramer, N.* ; Irmler, M. ; Stemmer, K. ; Sandoval, D.A.* ; Shah, Y.M.* ; Seeley, R.J.*
Gut HIF2α signaling is increased after VSG, and gut activation of HIF2α decreases weight, improves glucose, and increases GLP-1 secretion.
Cell Rep. 38:110270 (2022)
Gastric bypass and vertical sleeve gastrectomy (VSG) remain the most potent and durable treatments for obesity and type 2 diabetes but are also associated with iron deficiency. The transcription factor HIF2α, which regulates iron absorption in the duodenum, increases following these surgeries. Increasing iron levels by means of dietary supplementation or hepatic hepcidin knockdown does not undermine the effects of VSG, indicating that metabolic improvements following VSG are not secondary to lower iron levels. Gut-specific deletion of Vhl results in increased constitutive duodenal HIF2α signaling and produces a profound lean, glucose-tolerant phenotype that mimics key effects of VSG. Interestingly, intestinal Vhl deletion also results in increased intestinal secretion of GLP-1, which is essential for these metabolic benefits. These data demonstrate a role for increased duodenal HIF2α signaling in regulating crosstalk between iron-regulatory systems and other aspects of systemic physiology important for metabolic regulation.
Altmetric
Additional Metrics?
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Corresponding Author
Keywords
Bariatric Surgery ; Glp-1 ; Hypoxia-inducible Factor ; Iron Regulation ; Metabolic Surgery ; Obesity ; Type 2 Diabetes ; Vertical Sleeve Gastrectomy ; Von Hippel Lindau; Vertical Sleeve Gastrectomy; Gastric Bypass-surgery; Bariatric Surgery; Iron-deficiency; Medical Therapy; Homeostasis; Hif-2-alpha; Absorption
Keywords plus
ISSN (print) / ISBN
2211-1247
e-ISSN
2211-1247
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 38,
Issue: 3,
Pages: ,
Article Number: 110270
Supplement: ,
Series
Publisher
Cell Press
Publishing Place
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Grants
China Scholarship Council (CSC)
Novo Nordisk
'Deutsche Forschungsgemeinschaft (DFG)'
Michigan Diabetes Research Center, University of Michigan
University of Michigan
AstraZeneca
Pfizer
Eli Lilly and Company
National Cancer Institute of the National Institutes of Health (NIH)
MNORC
Helmholtz Alliance
German Center for Diabetes Research (BMBF)
GI Center